JialalI, DevarajS. Statin therapy for the metabolic syndrome: The evidence base. Metab Syndr Relat Disord, 2009; 7:393–395.
2.
DevarajS, ChanE, JialalI. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab, 2006; 91:4489–4496.
3.
JialalI, AbbeySL, MisirS, NagendranS. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: A pooled analysis. Metab Syndr Relat Disord, 2009; 7:255–258.
4.
The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365:2255–2267.
5.
JialalI, AmessW, KaurM. Management of hypertriglyceridemia in the diabetic patient. Curr Diab Rep, 2010; 10:316–320.
6.
The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet, 2005; 366:1849–1861.
7.
ScottR, O'BrienR, FulcherG, PardyCM, d'EmdenM, TseD, TaskinenMR, EhnholC, KeechA. The FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Diabetes Care, 2009; 32:493–498.
8.
TenenbaumA, MotroM, FismanEZ, TanneD, BoykoV, BeharS. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med, 2005; 165:1154–1160.
9.
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362:1563–1574.
10.
GinsbergH. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses. Diabetes Care, 2011; 34,Suppl 2:s107–s108.
